LAGUNA HILLS, Calif., Feb. 20, 2014 /PRNewswire/ -- Sonendo®, Inc., the developer of a revolutionary technology for the endodontic marketplace, announced today that its novel Multisonic Ultracleaning System™ was cited in the current online February issue of the Journal of Endodontics as having the ability to dissolve tissue at a significantly faster rate compared to current treatment methods. The study, "Tissue Dissolution by a Novel Multisonic Ultracleaning System and Sodium Hypochlorite," compared Sonendo's mechanism of action to a variety of conventional devices, and was found to dissolve tissue at least eight times faster than the other systems tested. The work was led by Prof. Markus Haapasalo, DDS, PhD, of University of British Columbia, Canada.
"The study results show very clearly the difference between the novel Multisonic Ultracleaning System versus the others examined," stated Prof. Haapasalo.
Bjarne Bergheim, President and CEO of Sonendo, noted that the study underscores the clinical value and importance of the Company's Multisonic Ultracleaning System as a completely new approach to root canal therapy.
"It is exciting to see the results of this study as it does, in a large way, validate the disruptive nature of our innovation here at Sonendo," Bergheim stated. "Very soon, endodontists will have the ability to perform root canal therapy for their patients in a completely different way, delivering an 'ultraclean' result more comprehensively, efficiently, and predictably. This study is one of many to come as we continue to build a body of sound science in order to meet the highest standards of any clinician."
Sonendo, Inc. is a privately-held, venture-backed company developing innovative and disruptive technologies to transform traditional endodontic therapy. In the United States alone, more than 15 million root canal procedures are performed each year. With the planned commercialization of its Multisonic Ultracleaning System™ set to launch in 2014, Sonendo aims to improve clinical quality and business economics of current root canal therapy. Sonendo investors include OrbiMed Advisors LLC, Themes Investment Partners, Fjord Ventures, and NeoMed Management. For more information please visit: www.sonendo.com.
This announcement contains forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management. All statements that address events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to the timing and progress of research and development activities. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. Sonendo does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.
SOURCE Sonendo, Inc.